Bausch + Lomb Launches R&D “Teach-in” Webinar Series
Bausch + Lomb Corporation (BLCO)
Company Research
Source: Business Wire
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D “Teach-in” webinar series that will provide deeper insights on the company’s differentiated product pipeline, which was unveiled in November 2025.On Monday, March 23, 2026, at 1:30 p.m. ET, Executive Vice President of Research & Development and Chief Medical Officer Yehia Hashad, MD, will be joined by members of his leadership team to discuss two glaucoma assets:BL1107, a glaucoma medication under development that would be the first to treat vision loss in addition to lowering intraocular pressureELIOS™, an implant-free minimally invasive glaucoma surgery approach using excimer laser precision to create outflow channels safely and effectively; already commercialized in Europe and backed by extensive clinical data (anticipated U.S. launch: 2H 2026)Chairman and CEO Brent Sau
Show less
Read more
Impact Snapshot
Event Time:
BLCO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLCO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLCO alerts
High impacting Bausch + Lomb Corporation news events
Weekly update
A roundup of the hottest topics
BLCO
News
- 3 Reasons BLCO is Risky and 1 Stock to Buy Instead [Yahoo! Finance]Yahoo! Finance
- A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript [Seeking Alpha]Seeking Alpha
- Ophthalmic Diagnostic Devices Market Size to Hit USD 5.22 Billion by 2035 Due to Growing Demand for Early Eye Disease Detection – SNS Insider [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma [Yahoo! Finance]Yahoo! Finance
BLCO
Earnings
- 2/18/26 - Miss
BLCO
Sec Filings
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- BLCO's page on the SEC website